Yolande Cordeaux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yolande Cordeaux has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- D. Stephen Charnock-Jones
Department of Obstetrics and Gynaecology, University of Cambridge, NIHR Cambridge Biomedical Research Centre, Cambridge, UK
3 shared publications - Gordon C. S. Smith
Department of Obstetrics and Gynaecology, University of Cambridge, NIHR Cambridge Biomedical Research Centre, Cambridge, UK
3 shared publications - Dharmintra Pasupathy
Reproduction and Perinatal Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
1 shared publication Hannah Missfelder-Lobos
1 shared publicationJoanne Bacon
Department of Obstetrics and Gynaecology University of Cambridge Cambridge United Kingdom
1 shared publicationMark Tattersall
Department of Obstetrics and Gynaecology, University of Cambridge, Rosie Hospital, Cambridge CB2 0SW, United Kingdom
1 shared publication
Latest Publications
- 1 December 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (12) , E437-E447
Effects of Medroxyprogesterone Acetate on Gene Expression in Myometrial Explants from Pregnant Women
Context: Progesterone is important physiologically and therapeutically to maintain uterine quiescence during pregnancy, in part through controlling myometrial gene expression. Objective: The objective of the study was to use expression microarray and quantitative reverse transcriptase-PCR (qRT-PCR) validation to determine the changes in gene expression induced by prolonged exposure of human myometrium to a synthetic progestogen. Design: Myometrial explants, obtained at elective cesarean section (n = 9), were maintained in culture, under 0.6 g tension, for 65 h in the presence of medroxyprogesterone acetate (100 nm) or vehicle. Expression array was performed using Illumina beadchip arrays. Approximately 30% of differentially expressed transcripts were validated in biological replicates (n = 10) by qRT-PCR. Results: The 114 significantly regulated transcripts were significantly enriched in inflammatory response (P = 0.00001), growth factor activity (P = 0.0004), and cytokine activity genes (P = 0.008). Thirty-four transcripts were validated using qRT-PCR in explants obtained from 10 further women. There was very close agreement in the fold changes obtained by array and qRT-PCR (r2 = 0.9, P < 0.0001). We confirmed significant down-regulation of a number of genes that have been well characterized as progesterone sensitive (IL-1B, IL-6, PTGS2, and GJA1). However, the top and sixth most down-regulated transcripts encoded two cytokines, IL-11 and IL-24, respectively, not previously implicated in mediating the effects of progesterone in myometrium. Both were validated by qRT-PCR (4.3- and 2.2-fold down-regulated, both P < 0.001). Conclusions: Medroxyprogesterone acetate controls expression of multiple genes in myometrium, including many that have not previously been characterized as progestogen regulated in this tissue, including IL-11 and IL-24. It is plausible that proteins encoded by some of these genes may have important but as yet uncharacterized effects in controlling human parturition.
- 1 December 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (12) , E437-E447
Effects of Medroxyprogesterone Acetate on Gene Expression in Myometrial Explants from Pregnant Women
Context: Progesterone is important physiologically and therapeutically to maintain uterine quiescence during pregnancy, in part through controlling myometrial gene expression. Objective: The objective of the study was to use expression microarray and quantitative reverse transcriptase-PCR (qRT-PCR) validation to determine the changes in gene expression induced by prolonged exposure of human myometrium to a synthetic progestogen. Design: Myometrial explants, obtained at elective cesarean section (n = 9), were maintained in culture, under 0.6 g tension, for 65 h in the presence of medroxyprogesterone acetate (100 nm) or vehicle. Expression array was performed using Illumina beadchip arrays. Approximately 30% of differentially expressed transcripts were validated in biological replicates (n = 10) by qRT-PCR. Results: The 114 significantly regulated transcripts were significantly enriched in inflammatory response (P = 0.00001), growth factor activity (P = 0.0004), and cytokine activity genes (P = 0.008). Thirty-four transcripts were validated using qRT-PCR in explants obtained from 10 further women. There was very close agreement in the fold changes obtained by array and qRT-PCR (r2 = 0.9, P < 0.0001). We confirmed significant down-regulation of a number of genes that have been well characterized as progesterone sensitive (IL-1B, IL-6, PTGS2, and GJA1). However, the top and sixth most down-regulated transcripts encoded two cytokines, IL-11 and IL-24, respectively, not previously implicated in mediating the effects of progesterone in myometrium. Both were validated by qRT-PCR (4.3- and 2.2-fold down-regulated, both P < 0.001). Conclusions: Medroxyprogesterone acetate controls expression of multiple genes in myometrium, including many that have not previously been characterized as progestogen regulated in this tissue, including IL-11 and IL-24. It is plausible that proteins encoded by some of these genes may have important but as yet uncharacterized effects in controlling human parturition.
- Open Access
- 1 March 2009
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 328 (3) , 682-691
Characterization of Serotonin Receptors in Pregnant Human Myometrium
The monoamine, 5-hydroxytryptamine (5-HT), stimulates contraction of human uterine smooth muscle (myometrium), but the receptor subtypes involved have not been characterized. We studied the effects of a range of 5-HT receptor subtype-selective agonists and antagonists in isolated strips of myometrium obtained at the time of caesarean section. The 5-HT1A receptor agonist, 8-hydroxy-2-dipropylaminotetralin, produced an increase in contractions that was highly variable, of low potency, and was not significantly inhibited by the 5-HT1A antagonist WAY100635 [[O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide]. The 5-HT2 receptor agonist, α-methyl-5-hydroxytryptamine (α-Me-5-HT), produced a strong, consistent, and concentration-dependent stimulation of contractions (pEC50 = 7.60 ± 0.10, n = 5). The 5-HT2A receptor antagonist, ketanserin [3-[2-[4-(4-fluoro benzoyl)-piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione], caused a parallel shift in the response to α-Me-5-HT, with a pKB value consistent with its known affinity for the 5-HT2A receptor (pKB = 8.47 ± 0.16, n = 5), but it had no effect on the response to oxytocin. The 5-HT2B and 5-HT2C receptor agonists, BW723C86 [(α-methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine)] and Ro-60-01-75 [(S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methyl-ethylamine fumarate], produced inconsistent responses at potencies that were lower than expected for activation of their cognate receptors. The response to α-Me-5-HT was unaffected by the 5-HT2B and 5-HT2C receptor antagonists, SB204741 [(N-(1-methyl-1H-indolyl-5-yl)-N-(3-methyl-5-isothiazolyl)urea)] and RS102221 [8-[5-(2,4-dimethoxy-5-(4-trifluoromethyl phenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione]. The 5-HT1B/1D receptor agonist, sumatriptan [1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide], the 5-HT4 agonist, cisapride [4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidyl]-2-methoxy-benzamide], and the 5-HT7 agonist, AS19 [(2S)-(+)-5-(1,3,5-trimethylpyrazol-4-yl)-2-(dimethylamino)tetralin], all had no effect on myometrial contractility. 5-HT2A receptor mRNA and immunoreactivity were identified using reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry. Specific binding of [3H]ketanserin was demonstrated. This study provides strong evidence for the expression of contractile 5-HT2A receptors in pregnant human myometrium, and this receptor is a potential target for novel uterotonic therapies.
- 1 March 2009
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 328 (3) , 682-691
Open AccessCharacterization of Serotonin Receptors in Pregnant Human Myometrium
The monoamine, 5-hydroxytryptamine (5-HT), stimulates contraction of human uterine smooth muscle (myometrium), but the receptor subtypes involved have not been characterized. We studied the effects of a range of 5-HT receptor subtype-selective agonists and antagonists in isolated strips of myometrium obtained at the time of caesarean section. The 5-HT1A receptor agonist, 8-hydroxy-2-dipropylaminotetralin, produced an increase in contractions that was highly variable, of low potency, and was not significantly inhibited by the 5-HT1A antagonist WAY100635 [[O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide]. The 5-HT2 receptor agonist, α-methyl-5-hydroxytryptamine (α-Me-5-HT), produced a strong, consistent, and concentration-dependent stimulation of contractions (pEC50 = 7.60 ± 0.10, n = 5). The 5-HT2A receptor antagonist, ketanserin [3-[2-[4-(4-fluoro benzoyl)-piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione], caused a parallel shift in the response to α-Me-5-HT, with a pKB value consistent with its known affinity for the 5-HT2A receptor (pKB = 8.47 ± 0.16, n = 5), but it had no effect on the response to oxytocin. The 5-HT2B and 5-HT2C receptor agonists, BW723C86 [(α-methyl-5-(2-thienylmethoxy)-1H-indole-3-ethanamine)] and Ro-60-01-75 [(S)-2-(6-chloro-5-fluoro-indol-1-yl)-1-methyl-ethylamine fumarate], produced inconsistent responses at potencies that were lower than expected for activation of their cognate receptors. The response to α-Me-5-HT was unaffected by the 5-HT2B and 5-HT2C receptor antagonists, SB204741 [(N-(1-methyl-1H-indolyl-5-yl)-N-(3-methyl-5-isothiazolyl)urea)] and RS102221 [8-[5-(2,4-dimethoxy-5-(4-trifluoromethyl phenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione]. The 5-HT1B/1D receptor agonist, sumatriptan [1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide], the 5-HT4 agonist, cisapride [4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidyl]-2-methoxy-benzamide], and the 5-HT7 agonist, AS19 [(2S)-(+)-5-(1,3,5-trimethylpyrazol-4-yl)-2-(dimethylamino)tetralin], all had no effect on myometrial contractility. 5-HT2A receptor mRNA and immunoreactivity were identified using reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry. Specific binding of [3H]ketanserin was demonstrated. This study provides strong evidence for the expression of contractile 5-HT2A receptors in pregnant human myometrium, and this receptor is a potential target for novel uterotonic therapies.
- 1 September 2008
- Published by Springer Nature in Reproductive Sciences
- Vol. 15 (7) , 727-734
Stimulation of Contractions in Human Myometrium by Serotonin is Unmasked by Smooth Muscle Relaxants
Objective. The aim of this study was to investigate the ability of serotonin to increase contractions in human myometrium. Methods. Isometric tension measurements were used to determine the effect of increasing doses of serotonin on strips of human myometrium obtained at the time of cesarean section. Results. Serotonin had little or no effect on the spontaneous activity of myometrium strips in control conditions. In tissue where this activity had been reduced by either forskolin or diazoxide, serotonin caused a dose-dependent increase in contractions and produced up to a 3-fold increase in contractions over basal activity. Conclusions.The ability of serotonin to increase contractions in the uterus appears to depend on the background activity of the tissue and is greatest in quiescent tissue. It is therefore possible that in quiescent, preterm myometrium, aberrant serotonin signaling could contribute to preterm labor. Serotonin may also play a key role in the postpartum prevention of uterine atony and consequent hemorrhage.
- 1 September 2008
- Published by Springer Nature in Reproductive Sciences
- Vol. 15 (7) , 727-734
Stimulation of Contractions in Human Myometrium by Serotonin is Unmasked by Smooth Muscle Relaxants
Objective. The aim of this study was to investigate the ability of serotonin to increase contractions in human myometrium. Methods. Isometric tension measurements were used to determine the effect of increasing doses of serotonin on strips of human myometrium obtained at the time of cesarean section. Results. Serotonin had little or no effect on the spontaneous activity of myometrium strips in control conditions. In tissue where this activity had been reduced by either forskolin or diazoxide, serotonin caused a dose-dependent increase in contractions and produced up to a 3-fold increase in contractions over basal activity. Conclusions.The ability of serotonin to increase contractions in the uterus appears to depend on the background activity of the tissue and is greatest in quiescent tissue. It is therefore possible that in quiescent, preterm myometrium, aberrant serotonin signaling could contribute to preterm labor. Serotonin may also play a key role in the postpartum prevention of uterine atony and consequent hemorrhage.